

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001838777
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer ImmunoGen, Inc.
SEC File Number 000-17999
Address of Issuer 830 WINTER ST
WALTHAM
MASSACHUSETTS
02451
Phone (781)895-0600
Name of Person for Whose Account the Securities are To Be Sold Lentini Renee

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	219545	3356795.78	266264274	11/06/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this Acquired	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	-----------------------------------	------------------	---------------------	-------------------------------	-----------------	---------------------

						a	
						Gift?	
Common Stock	11/06/2023	Exercise of employee stock options	ImmunoGen, Inc.	<input type="checkbox"/>	120528	11/06/2023	Broker assisted cashless exercise
Common Stock	06/30/2023	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	3195	06/30/2023	Cash
Common Stock	12/30/2022	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	1351	12/30/2022	Cash
Common Stock	06/30/2022	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	2509	06/30/2022	Cash
Common Stock	12/31/2021	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	1957	12/31/2021	Cash
Common Stock	06/30/2021	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	1683	06/30/2021	Cash
Common Stock	12/31/2020	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	3725	12/31/2020	Cash
Common Stock	06/30/2020	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	1531	06/30/2020	Cash
Common Stock	12/31/2019	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	2902	12/31/2019	Cash
Common Stock	12/31/2018	Employee stock purchase plan program	ImmunoGen, Inc.	<input type="checkbox"/>	2455	12/31/2018	Cash
Common Stock	09/12/2023	Cash exercise of employee stock options	ImmunoGen, Inc.	<input type="checkbox"/>	25141	09/12/2023	Cash
Common Stock	08/03/2023	Cash exercise of employee stock options	ImmunoGen, Inc.	<input type="checkbox"/>	51033	08/03/2023	Cash
Common Stock	03/18/2014	Cash exercise of employee stock options	ImmunoGen, Inc.	<input type="checkbox"/>	1535	03/18/2014	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

11/06/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Renee Lentini

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)